International Journal of Medical and Pharmaceutical Research
2025, Volume-6, Issue-4 : 450-457 doi: 10.5281/zenodo.16786382
Original Article
A comparative study of efficacy of intralesional triamcinolone, topical silicone gel sheet and intralesional triamcinolone plus topical silicone gel sheet in treatment of keloid or hypertrophic scar
 ,
 ,
 ,
 ,
 ,
Published
Aug. 9, 2025
Abstract

Background: There is no universally accepted treatment resulting in permanent hypertrophic or keloid scar ablation. Multiple modalities of treatment have been advocated. Most of these modalities have a variable and transient success. Hence there is need for evaluation of better modalities to achieve good cosmetic acceptability. Aim: To study the efficacy and safety of intralesional triamcinolone, topical silicone gel sheet and intralesional triamcinolone plus topical silicone gel sheet in treatment of keloid or hypertrophic scar. Methods: Total 150 patients with keloid or hypertrophic scar, randomly divided into three groups (50 each), treated with intralesional triamcinolone (Group A), topical silicone gel sheet (Group B) and intralesional triamcinolone plus topical silicone gel sheet (Group C) for a maximum period of 6 month. The groups were compared for reduction in size and the side effects. Ultrasonography of the lesions using 10- 12 MHz Linear transducer was done to assess the baseline dimension before starting the treatment & at the end of the study period. Clinical improvement was assessed by photography & measurement scale serially till the scar flattened at each visit. Results: The overall therapeutic response in terms of size reduction in group C was found to be better and statistically significant (p value < 0. 01) compare d to group A & B. Conclusion: Combination therapy was more effective with faster results and few side effects.

Recommended Articles
Loading Image...
Volume-6, Issue-4
Citations
1762 Views
158 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved